Rocket Pharmaceuticals (RCKT) Expected to Announce Quarterly Earnings on Thursday

Rocket Pharmaceuticals (NASDAQ:RCKT) is expected to be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of $1.04 per share and revenue of $0.2220 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). During the same period in the previous year, the company posted ($0.56) EPS. On average, analysts expect Rocket Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rocket Pharmaceuticals Price Performance

NASDAQ RCKT opened at $3.41 on Tuesday. The stock has a market capitalization of $372.34 million, a P/E ratio of -1.82 and a beta of 0.47. Rocket Pharmaceuticals has a 1 year low of $2.53 and a 1 year high of $5.45. The business’s fifty day moving average is $3.29 and its two-hundred day moving average is $3.62. The company has a debt-to-equity ratio of 0.08, a quick ratio of 6.12 and a current ratio of 6.12.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Weiss Ratings upgraded Rocket Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Chardan Capital reiterated a “buy” rating and issued a $11.00 price target on shares of Rocket Pharmaceuticals in a research report on Monday, May 11th. Finally, Wall Street Zen raised shares of Rocket Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, Rocket Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $8.71.

Insider Activity

In other Rocket Pharmaceuticals news, insider Sarbani Chaudhuri sold 17,650 shares of Rocket Pharmaceuticals stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $3.84, for a total transaction of $67,776.00. Following the transaction, the insider owned 267,510 shares of the company’s stock, valued at $1,027,238.40. The trade was a 6.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Gaurav Shah sold 55,684 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $3.09, for a total transaction of $172,063.56. Following the sale, the chief executive officer owned 1,061,724 shares of the company’s stock, valued at approximately $3,280,727.16. This represents a 4.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 83,733 shares of company stock worth $275,307. Company insiders own 21.30% of the company’s stock.

Hedge Funds Weigh In On Rocket Pharmaceuticals

A number of hedge funds have recently modified their holdings of RCKT. Abel Hall LLC acquired a new stake in Rocket Pharmaceuticals in the fourth quarter valued at approximately $50,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Rocket Pharmaceuticals in the third quarter worth about $47,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Rocket Pharmaceuticals in the third quarter worth about $50,000. Marex Group plc bought a new position in shares of Rocket Pharmaceuticals in the 2nd quarter valued at approximately $55,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Rocket Pharmaceuticals by 645.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 23,258 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 20,138 shares in the last quarter. 98.39% of the stock is owned by institutional investors and hedge funds.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.